FDA Approves Pfizer’s Braftovi + Mektovi Combo for BRAF V600E Metastatic NSCLC
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) regulatory approval for...
China Introduces Trial Measures for Science and Technology Ethics Review
The National Health Commission, Ministry of Science and Technology, Ministry of Education, and eight other...
Roche’s Ocrevus Demonstrates Long-Term Efficacy in Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has presented compelling long-term efficacy data for its selective...
China Releases First Supplement to 2020 Pharmacopoeia with 47 New Drug Varieties
The National Medical Products Administration (NMPA) and the National Health Commission have announced the release...
Sichuan Huiyu Pharmaceutical’s HYP2090PTSA Gains NMPA Approval for KRAS G12C Solid Tumors
Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...
Livzon Pharmaceutical Secures Licensing Agreement for LanssonPharm’s PDE4 Inhibitor in China
China-based Livzon Pharmaceutical Group Inc., (HKG: 1513, SHE: 000513) has announced a significant licensing agreement...
AbbVie’s Rinvoq Demonstrates Sustained Efficacy in Late-Stage Atopic Dermatitis Study
AbbVie (NYSE: ABBV) has announced late-stage results for its JAK inhibitor Rinvoq (upadacitinib) in the...
China’s Healthcare Landscape: Key Insights from the 2022 Statistical Communique
The National Health Commission (NHC) has released “China’s Healthcare Statistical Communique 2022,” providing a comprehensive...
Lee’s Pharmaceutical’s Subsidiary Announces Positive Results for Myopia Treatment NVK002
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...
J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...
Nanjing Geneseeq’s NSCLC TMB Detection Kit Approved by NMPA
China-based Nanjing Geneseeq Medical Device and Diagnostic Inc. has announced that its tissue tumor mutation...
RemeGen Secures NMPA Approval for Phase II Study of Disitamab Vedotin in Breast Cancer
China-based biopharma RemeGen Ltd (HKG: 9995) has announced that it has received approval from the...
Genetron Holdings Enters Privatization Agreement with Consortium
Beijing-based Genetron Holdings Ltd (NASDAQ: GTH) has officially entered into a privatization and merger agreement...
Ascentage Pharma Initiates Phase III Study for APG-2575 and Calquence in CLL/SLL
Suzhou-based Ascentage Pharma (HKG: 6855) has announced the approval to commence a global multi-center, randomized,...
Betta Pharmaceuticals Secures NMPA Approval for Befotertinib in NSCLC Treatment
China-based Betta Pharmaceuticals Co., Ltd. (SHE: 300558) has officially announced its receipt of market approval...
KPC Pharmaceuticals Secures WHO Prequalification for Dihydroartemisinin/Piperaquine
Yunnan-based KPC Pharmaceuticals Inc. (SHA: 600422) has announced that its dihydroartemisinin/piperaquine 40mg/320mg formulation has received...
Novartis Halts Phase II Clinical Study for MIJ821 in Major Depressive Disorder
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has decided to hold the Phase II clinical...
MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
Bayer AG Plans Continued Investment in China Amidst Global Challenges
Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as...
Novo Nordisk Halts Phase III Ozempic Study on Renal Impairment in Diabetes Patients
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has decided to discontinue a Phase III global...